Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Status:
Completed
Trial end date:
2005-07-15
Target enrollment:
Participant gender:
Summary
Subjects are randomized to one of two treatment arms. All subjects are screened for
eligibility within 28 days prior to randomization. The study consists of a treatment phase
and a follow-up phase. Subjects are treated in repeating 4 week cycles.